Catalogo dei prodotti della ricerca

ALFARONE, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.754
EU - Europa 479
AS - Asia 307
AF - Africa 24
SA - Sud America 6
OC - Oceania 2
Totale 2.572
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.746
IT - Italia 149
SG - Singapore 122
CN - Cina 103
SE - Svezia 92
IN - India 80
UA - Ucraina 79
FI - Finlandia 62
DE - Germania 45
TG - Togo 23
GB - Regno Unito 13
RU - Federazione Russa 11
CA - Canada 8
AR - Argentina 6
BE - Belgio 6
BG - Bulgaria 6
NL - Olanda 5
FR - Francia 3
EE - Estonia 2
ID - Indonesia 2
IE - Irlanda 2
MK - Macedonia 2
AU - Australia 1
CH - Svizzera 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
SC - Seychelles 1
Totale 2.572
Salva come PNG Salva come JPEG
Città #
Fairfield 297
Woodbridge 158
Chandler 144
Ashburn 112
Ann Arbor 99
Seattle 98
Singapore 93
Houston 91
Cambridge 88
Rome 79
Wilmington 74
Santa Clara 55
Princeton 54
Plano 42
San Paolo di Civitate 38
Beijing 29
Jacksonville 28
Millbury 27
Lawrence 24
Lomé 23
Falkenstein 21
Helsinki 20
San Diego 20
Des Moines 18
Hefei 16
Dearborn 15
Andover 14
Falls Church 14
Boston 12
Kunming 12
Boardman 10
Munich 10
Norwalk 10
San Mateo 9
Toronto 7
Brussels 6
Federal 6
Sofia 6
Guangzhou 5
Jinan 5
Southend 5
Amsterdam 4
Bühl 4
Milan 4
Fuzhou 3
Mannheim 3
Nanchang 3
Auburn Hills 2
Chengdu 2
Chongqing 2
Dublin 2
Eboli 2
Indiana 2
Jakarta 2
Los Angeles 2
Moscow 2
Nanjing 2
Ningbo 2
Paris 2
Shenyang 2
Skopje 2
Tallinn 2
Wuhan 2
Zhengzhou 2
Aprilia 1
Asti 1
Auckland 1
Bangor 1
Baotou 1
Bari 1
Birmensdorf 1
Buffalo 1
Büdelsdorf 1
Clearwater 1
Columbus 1
Frankfurt am Main 1
Fremont 1
Grafing 1
Hangzhou 1
Harbin 1
Hebei 1
Jinhua 1
Las Vegas 1
London 1
Monmouth Junction 1
Nanning 1
Napoli 1
New York 1
Olinda 1
Ottawa 1
Provo 1
Redmond 1
Redwood City 1
Riga 1
Sacramento 1
San Francisco 1
Scafati 1
Shanghai 1
Stockholm 1
Tappahannock 1
Totale 1.985
Salva come PNG Salva come JPEG
Nome #
Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer 113
Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy 105
New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): Current status and future prospects 89
Use of Multiparametric MR with Neurovascular Bundle Evaluation to Optimize the Oncological and Functional Management of Patients Considered for Nerve-Sparing Radical Prostatectomy 87
Early recovery of urinary continence after radical prostatectomy using early pelvic floor electric stimulation and biofeedback associated treatment 86
Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer 78
Etoricoxib and intermittent androgen deprivation (IAD) therapy in patients with biochemical progression after radical prostatectomy 78
Early Recovery of Urinary Continence After Radical Prostatectomy Using Early Pelvic Floor Electrical Stimulation and Biofeedback Associated Treatment 74
Value of magnetic resonance spectroscopy (MSR) and dynamic contrast-enhanced magnetic resonance (DCEMR) imaging for the characterization of high-grade prostatic intraepithelial neoplasia (HGPIN) foci 74
Use of multiparametric MR with neurovascular bundle evaluation to optimize the oncological and functional management of patients considered for nerve sparing radical prostatectomy 73
Prognostic predictors in prostate cancer cases with biochemical progression after surgery treated with intermittent androgen deprivation (IAD) 72
USE OF MULTIPARAMETRIC MR WITH NEUROVASCULAR BUNDLE EVALUATION TO OPTIMIZE THE ONCOLOGICAL AND FUNCTIONAL MANAGEMENT OF PATIENTS CONSIDERED FOR NERVE SPARING RADICAL PROSTATECTOMY 72
Prostate cancer unit for an optimal management of prostate cancer unit. ["Prostate cancer unit" per un management ottimale dei pazienti con tumore prostatico] 72
Chromogranin A and biochemical progression free survival in prostate adenocarcinomas submitted to radical prostatectomy 70
Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): Pattern changes from inflammation to prostate cancer 69
Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR) 67
Current diagnostic procedure on neuroendocrine differentiation of prostate cancer 66
Esperienza a lungo termine con un approccio anatomico anterogrado alla prostatectomia radicale (RRP): risultati in termini di margini chirurgici 65
Etoricoxib and intermittent androgen deprivation (IAD) therapy in patients with biochemical progression after radical prostatectomy 65
Update on screening in prostate cancer based on recent clinical trials 64
Supernumerary kidney laparoscopically treated 64
Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy 64
PROGNOSTIC PREDICTORS IN PROSTATE CANCER CASES WITH BIOCHEMICAL PROGRESSION AFTER SURGERY TREATED WITH INTERMITTENT ANDROGEN DEPRIVATION (IAD) 63
Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery 62
The emerging role of targeted therapy in renal cell carcinoma (RCC): Is it time for a neoadjuvant or an adjuvant approach? 59
Distribution of High Chromogranin A Serum Levels in Patients with Nonmetastatic and Metastatic Prostate Adenocarcinoma 59
Role of neuroendocrine cells in prostate cancer progression 58
Use of 3D T2-Weighted MR Sequences for the Assessment of Neurovascular Bundle Changes after Nerve-Sparing Radical Retropubic Prostatectomy (RRP): A Potential Diagnostic Tool for Optimal Management of Erectile Dysfunction after RRP 58
Actual role of multitargeted therapy in renal cell carcinoma (RCC) 56
Cryotherapy for prostate cancer 55
Ipertrofia prostatica benigna: una patologia in progressione. Ipotesi per una terapia preventiva 55
Cromogranin A e rischio di progressione biochimica dopo prostatectomia radicale per adenocarcinoma prostatico: follow-up fino a 10 anni. 48
Cellule dendridiche (DC)123+ linfoidi e cellule dendridiche (DC)11c+ mieloidi circolanti nel sangue di pazienti affetti da adenocarcinoma prostatico. 48
Distribuzione dei livelli sierici di cromogranina A nei pazienti con adenocarcinoma prostatico non metastatico e metastatico. 47
Esperienza a lungo termine con approccio anatomico anterogrado alla prostatectomia radicale: risultati in termini di margini chirurgici positivi 46
Oral ethinylestradiol in castration resistent prostate cancer: 10 year experience 38
Ruolo della risonanza magnetica con spettroscopia nella diagnosi delle recidive dopo prostatectomia radicale: correlazione con i livelli sierici di PSA e Gleason score 38
PROSTATE CANCER UNITS FOR THE OPTIMAL MANAGEMENT OF PROSTATE CANCER 32
THE ONCOGENIC POTENTIAL OF HUMAN POLYOMAVIRUSIIK IN PROSTATE CANCER 29
Utilizzo degli inibitori della cicloossigenasi 2 nella prevenzione delle stenosi uretrali secondarie a resezione transuretrale della prostata. 27
null 26
Role of dynamic contrast enhanced magnetic resonance imaging and proton MR spectroscopic imaging in the detectionof local recurrence after radical prostatectomy for prostate cancer 23
Totale 2.594
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.710
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.710
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020414 0 0 0 0 0 93 104 75 71 35 20 16
2020/2021207 21 29 12 59 3 6 4 19 21 16 16 1
2021/2022422 6 23 50 7 55 15 6 48 26 37 56 93
2022/2023493 94 110 44 47 44 68 1 26 47 0 8 4
2023/2024156 20 39 2 18 12 7 0 8 1 22 15 12
2024/2025227 18 21 40 20 67 61 0 0 0 0 0 0
Totale 2.594